SG11201607015VA - V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS - Google Patents
V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICSInfo
- Publication number
- SG11201607015VA SG11201607015VA SG11201607015VA SG11201607015VA SG11201607015VA SG 11201607015V A SG11201607015V A SG 11201607015VA SG 11201607015V A SG11201607015V A SG 11201607015VA SG 11201607015V A SG11201607015V A SG 11201607015VA SG 11201607015V A SG11201607015V A SG 11201607015VA
- Authority
- SG
- Singapore
- Prior art keywords
- proteins exhibiting
- exhibiting distinct
- antigen binding
- binding proteins
- binding characteristics
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968896P | 2014-03-21 | 2014-03-21 | |
| US201462079078P | 2014-11-13 | 2014-11-13 | |
| US201462088117P | 2014-12-05 | 2014-12-05 | |
| PCT/US2015/021884 WO2015143406A2 (en) | 2014-03-21 | 2015-03-20 | Vl antigen binding proteins exhibiting distinct binding characteristics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607015VA true SG11201607015VA (en) | 2016-09-29 |
Family
ID=52815322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201808083VA SG10201808083VA (en) | 2014-03-21 | 2015-03-20 | Vl antigen binding proteins exhibiting distinct binding characteristics |
| SG11201607015VA SG11201607015VA (en) | 2014-03-21 | 2015-03-20 | V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201808083VA SG10201808083VA (en) | 2014-03-21 | 2015-03-20 | Vl antigen binding proteins exhibiting distinct binding characteristics |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20150266976A1 (en) |
| EP (1) | EP3119811B1 (en) |
| JP (1) | JP2017510273A (en) |
| KR (1) | KR20160131118A (en) |
| CN (1) | CN106164092A (en) |
| AU (1) | AU2015231025A1 (en) |
| BR (1) | BR112016021679A2 (en) |
| CA (1) | CA2941514A1 (en) |
| ES (1) | ES2762640T3 (en) |
| HK (1) | HK1231497A1 (en) |
| IL (1) | IL247488A0 (en) |
| MX (1) | MX2016012273A (en) |
| RU (1) | RU2016141123A (en) |
| SG (2) | SG10201808083VA (en) |
| WO (1) | WO2015143406A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55495B1 (en) | 2010-08-02 | 2017-04-28 | Regeneron Pharma | Mice That Bind Proteins Containing VL Domains |
| RU2016141123A (en) | 2014-03-21 | 2018-04-23 | Регенерон Фармасьютикалз, Инк. | VL ANTIGEN-BINDING PROTEINS MANIFESTING VARIOUS BINDING CHARACTERISTICS |
| JP6636498B2 (en) | 2014-03-21 | 2020-01-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| RS66700B1 (en) | 2016-06-03 | 2025-05-30 | Regeneron Pharma | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| IL318469A (en) * | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of engineered dh-dh rearrangement and uses thereof |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| WO2021142007A1 (en) * | 2020-01-09 | 2021-07-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Antibodies and method of producing antibodies |
| CN114196626A (en) * | 2022-02-16 | 2022-03-18 | 北京国卫生物科技有限公司 | Umbilical cord mesenchymal stem cells and isolated culture and amplification method thereof |
| CN120148649B (en) * | 2024-09-10 | 2025-08-19 | 安徽农业大学 | Nucleic acid binding protein recognition method based on protein map and protein language model |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4977081A (en) | 1987-05-04 | 1990-12-11 | Adi Diagnostics, Inc. | Stable rabbit-mouse hybridomas and secretion products thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU8212291A (en) | 1990-07-10 | 1992-02-04 | Nkk Corporation | Hybridoma which produces avian specific immunoglobulin g |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| EP0583980A1 (en) | 1992-08-20 | 1994-02-23 | Eli Lilly And Company | Method for generating monoclonal antibodies from rabbits |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE427968T1 (en) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | IMMUNOGLOBULINS WITHOUT LIGHT CHAIN |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| CZ140195A3 (en) | 1992-12-01 | 1996-06-12 | Protein Desing Labs | Humanized antibodies reacting with l-selectin |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| AU7326796A (en) | 1995-10-30 | 1997-05-22 | Spectral Diagnostics Inc. | Stable chicken b-cell line and method of use thereof |
| EP0907726A4 (en) | 1996-06-26 | 2001-11-07 | Baylor College Medicine | CHROMOSOME REARRANGEMENT BY INSERTING TWO RECOMBINANT SUBSTRATES |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| CN1203922A (en) | 1997-03-21 | 1999-01-06 | 三共株式会社 | Humanized anti-human fas antibody |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| CA2373638A1 (en) | 1999-05-27 | 2000-12-07 | Human Genome Sciences, Inc. | Adam polynucleotides and polypeptides |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| US7034134B2 (en) | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
| US7476536B2 (en) | 2001-05-11 | 2009-01-13 | Kirin Pharma Kabushiki Kaisha | Artificial human chromosome containing human antibody a light chain gene |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| CA2447851C (en) | 2001-06-28 | 2012-08-28 | Domantis Limited | Dual-specific ligand and its use |
| FR2827302B1 (en) | 2001-07-13 | 2003-10-10 | Genoway | TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF |
| US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
| US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
| ES2645563T3 (en) | 2001-11-30 | 2017-12-05 | Amgen Fremont Inc. | Transgenic animals that carry human Ig light chain genes |
| WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| AU2003230741A1 (en) | 2002-03-22 | 2003-10-13 | Origen Therapeutics | Transgenic aves producing human polyclonal antibodies |
| DK1517921T3 (en) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunoglobulin single variable antigen binding domains and double specific constructs thereof |
| PT1523496E (en) | 2002-07-18 | 2011-09-29 | Merus B V | PRODUCTION OF RECOMBINANT ANTIBODY MIXTURES |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| GB0230201D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| EP1639009B1 (en) | 2003-05-30 | 2013-02-27 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2005001087A2 (en) | 2003-06-11 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Methods of modifying genes in eukaryotic cells |
| CN103205436B (en) | 2003-07-15 | 2016-05-25 | 人类多克隆治疗公司 | humanized immunoglobulin loci |
| WO2005019463A1 (en) | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis with humanized immunoglobulin loci |
| RU2251699C1 (en) | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Method for early and preclinical diagnostics of cervical cancer |
| WO2005038001A2 (en) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
| FR2861255B1 (en) | 2003-10-24 | 2006-02-17 | Centre Nat Rech Scient | NON-HUMAN TRANSGENIC MAMMAL FOR THE CONSTANT REGION OF THE HEAVY CHAIN OF HUMAN CLASS A IMMUNOGLOBULINS AND ITS APPLICATIONS |
| ES2523661T3 (en) | 2004-07-22 | 2014-11-28 | Erasmus University Medical Center Rotterdam | Binding molecules |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| WO2006047367A2 (en) | 2004-10-22 | 2006-05-04 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglubolin expression in non-human transgenic animals |
| RU2435784C2 (en) | 2006-01-25 | 2011-12-10 | Эрасмус Юниверсити Медикал Сентр Роттердам | Obtaining antibodies from same heavy chains in transgenic animals |
| GB0618345D0 (en) | 2006-09-18 | 2006-10-25 | Univ Erasmus | Binding molecules |
| AU2007235496B2 (en) | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| SG174053A1 (en) | 2006-09-01 | 2011-09-29 | Therapeutic Human Polyclonals Inc | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| MX2009003393A (en) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor. |
| NO347649B1 (en) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use. |
| PT2336329E (en) | 2007-06-01 | 2012-12-24 | Omt Inc | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies |
| WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
| CA2694488A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| EP2185692A4 (en) | 2007-08-10 | 2012-05-02 | Medarex Inc | Hco32 and hco27 and related examples |
| AU2008294074B2 (en) | 2007-08-30 | 2015-01-22 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| WO2009041613A1 (en) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2271758B1 (en) | 2008-04-14 | 2018-09-12 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
| EP2669298A3 (en) | 2008-05-23 | 2014-02-26 | Ablexis, LLC | Single variable immunoglobulin domain comprising VL-DH-JL |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| CN102123582B (en) | 2008-06-27 | 2015-09-30 | 莫鲁斯有限公司 | Antibody-producing non-human mammals |
| KR102362774B1 (en) | 2008-09-30 | 2022-02-15 | 아블렉시스, 엘엘씨 | Non-human mammals for the production of chimeric antibodies |
| US20110314563A1 (en) | 2008-12-18 | 2011-12-22 | Kingdon Craig R | Antibody production |
| CA2983133A1 (en) | 2009-02-04 | 2010-08-12 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| CN102361883A (en) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | Bispecific anti-erbb-1/anti-c-met antibodies |
| KR20120027055A (en) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
| NO2792236T3 (en) | 2009-07-08 | 2018-04-14 | ||
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| CN102711449B (en) | 2009-12-10 | 2015-01-07 | 瑞泽恩制药公司 | Mice producing heavy chain antibodies |
| PL3095871T3 (en) | 2010-02-08 | 2019-10-31 | Regeneron Pharma | A mouse that shares a common light chain |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| CN105695415A (en) | 2010-06-17 | 2016-06-22 | 科马布有限公司 | Animal models and therapeutic molecules |
| ME02902B (en) | 2010-06-22 | 2018-04-20 | Regeneron Pharma | Transgenic mice with a modified endogenous lambda immunoglobulin locus |
| RS55495B1 (en) * | 2010-08-02 | 2017-04-28 | Regeneron Pharma | Mice That Bind Proteins Containing VL Domains |
| PL2606064T3 (en) * | 2010-08-16 | 2015-07-31 | Novimmune Sa | Methods for the generation of multispecific and multivalent antibodies |
| EP2638155A1 (en) | 2010-11-08 | 2013-09-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
| ES2946169T3 (en) | 2011-02-25 | 2023-07-13 | Regeneron Pharma | ADAM6 Mice |
| WO2012116927A1 (en) * | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| MX341921B (en) * | 2011-02-28 | 2016-09-07 | Hoffmann La Roche | Antigen binding proteins. |
| IL273982B2 (en) | 2011-08-05 | 2023-03-01 | Regeneron Pharma | Humanized universal light chain mice |
| EP3741862A1 (en) | 2011-09-19 | 2020-11-25 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
| EP2758535B1 (en) | 2011-09-19 | 2016-11-09 | Kymab Limited | Antibodies, variable domains&chains tailored for human use |
| EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| KR20250021626A (en) | 2011-10-17 | 2025-02-13 | 리제너론 파마슈티칼스 인코포레이티드 | Restricted immunoglobulin heavy chain mice |
| GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| BR112014015238B1 (en) | 2011-12-20 | 2022-11-16 | Regeneron Pharmaceuticals, Inc | EX VIVO METHOD FOR PREPARING AN ANTIBODY THAT BINDS TO AN ANTIGEN OF INTEREST, INCLUDING IDENTIFYING NUCLEIC ACID SEQUENCES FROM MOUSE B LYMPHOCYTES GENETICALLY MODIFIED BY PLACING AN ADAM6 GENE |
| HRP20192218T1 (en) | 2012-02-01 | 2020-03-06 | Regeneron Pharmaceuticals, Inc. | Humanized mice that express heavy chains containing vl domains |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| WO2013149678A1 (en) | 2012-04-05 | 2013-10-10 | Novaled Ag | Organic field effect transistor and method for producing the same |
| TWI635098B (en) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | Antibodies comprising chimeric constant domains |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| KR20200136508A (en) | 2013-04-16 | 2020-12-07 | 리제너론 파마슈티칼스 인코포레이티드 | Targeted modification of rat genome |
| RU2016141123A (en) | 2014-03-21 | 2018-04-23 | Регенерон Фармасьютикалз, Инк. | VL ANTIGEN-BINDING PROTEINS MANIFESTING VARIOUS BINDING CHARACTERISTICS |
| JP6636498B2 (en) | 2014-03-21 | 2020-01-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
-
2015
- 2015-03-20 RU RU2016141123A patent/RU2016141123A/en not_active Application Discontinuation
- 2015-03-20 AU AU2015231025A patent/AU2015231025A1/en not_active Abandoned
- 2015-03-20 WO PCT/US2015/021884 patent/WO2015143406A2/en not_active Ceased
- 2015-03-20 EP EP15715047.5A patent/EP3119811B1/en active Active
- 2015-03-20 HK HK17105304.1A patent/HK1231497A1/en unknown
- 2015-03-20 CA CA2941514A patent/CA2941514A1/en not_active Abandoned
- 2015-03-20 KR KR1020167029189A patent/KR20160131118A/en not_active Withdrawn
- 2015-03-20 BR BR112016021679-2A patent/BR112016021679A2/en not_active Application Discontinuation
- 2015-03-20 CN CN201580015494.3A patent/CN106164092A/en active Pending
- 2015-03-20 SG SG10201808083VA patent/SG10201808083VA/en unknown
- 2015-03-20 US US14/664,750 patent/US20150266976A1/en not_active Abandoned
- 2015-03-20 JP JP2016558391A patent/JP2017510273A/en active Pending
- 2015-03-20 SG SG11201607015VA patent/SG11201607015VA/en unknown
- 2015-03-20 ES ES15715047T patent/ES2762640T3/en active Active
- 2015-03-20 MX MX2016012273A patent/MX2016012273A/en unknown
-
2016
- 2016-08-25 IL IL247488A patent/IL247488A0/en unknown
-
2018
- 2018-03-19 US US15/925,501 patent/US10787522B2/en active Active
-
2020
- 2020-08-18 US US16/996,302 patent/US20200377618A1/en not_active Abandoned
-
2023
- 2023-12-13 US US18/538,999 patent/US20240124613A1/en not_active Abandoned
-
2025
- 2025-07-09 US US19/264,536 patent/US20250340672A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180273641A1 (en) | 2018-09-27 |
| RU2016141123A (en) | 2018-04-23 |
| ES2762640T3 (en) | 2020-05-25 |
| SG10201808083VA (en) | 2018-10-30 |
| EP3119811B1 (en) | 2019-10-30 |
| US20240124613A1 (en) | 2024-04-18 |
| JP2017510273A (en) | 2017-04-13 |
| HK1231497A1 (en) | 2017-12-22 |
| US20150266976A1 (en) | 2015-09-24 |
| US10787522B2 (en) | 2020-09-29 |
| US20250340672A1 (en) | 2025-11-06 |
| CA2941514A1 (en) | 2015-09-24 |
| CN106164092A (en) | 2016-11-23 |
| IL247488A0 (en) | 2016-11-30 |
| KR20160131118A (en) | 2016-11-15 |
| WO2015143406A2 (en) | 2015-09-24 |
| AU2015231025A1 (en) | 2016-09-15 |
| BR112016021679A2 (en) | 2018-12-04 |
| RU2016141123A3 (en) | 2018-11-13 |
| EP3119811A2 (en) | 2017-01-25 |
| MX2016012273A (en) | 2017-02-23 |
| WO2015143406A3 (en) | 2015-11-26 |
| US20200377618A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804317B (en) | Altered april binding antibodies | |
| IL266143A (en) | Antibody constructs | |
| ZA201608609B (en) | Antibodies binding axl | |
| IL273393A (en) | Novel anti-cd3epsilon antibodies | |
| SG11201607015VA (en) | V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | |
| GB201601073D0 (en) | Antibodies | |
| ZA201701912B (en) | Antigen binding proteins that bind cxcr5 | |
| GB201411420D0 (en) | Antibody constructs | |
| EP3266872A4 (en) | Novel anti-pad4 antibody | |
| LT3166970T (en) | IMPROVED A-BETA PROTOFIBRILE BINDING ANTIBODIES | |
| EP3170841A4 (en) | NOVEL ANTI-HUMAN Tie2 ANTIBODY | |
| ZA201604640B (en) | Novel anti-netrin-1 antibody | |
| GB201603291D0 (en) | Antibodies | |
| EP3131574A4 (en) | Antigen binding proteins that bind wisp1 | |
| IL250404A0 (en) | Novel anti-human igbeta antibody | |
| EP3112463A4 (en) | Novel anti-presepsin antibody | |
| ZA201701941B (en) | Antigen binding proteins that bind cxcr3 | |
| ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
| GB201614627D0 (en) | Antigen binding proteins | |
| EP3198065A4 (en) | Antibody like protein | |
| HK1233533A1 (en) | Antigen binding proteins that bind wisp1 | |
| GB201715149D0 (en) | IL-ß binding antibody |